Peeters Protides of the BIological Fluids

Proceedings of the Thirtieth Colloquium, 1982
1. Auflage 2014
ISBN: 978-1-4832-7964-0
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 30, 800 Seiten, Web PDF

Reihe: Protides of the Biological Fluids

Protides of the Biological Fluids: Proceedings of the 30th Colloquium, 1982 is a collection of manuscripts presented at the 30th Colloquium, held in Brussels, Belgium in 1982. This text is organized into three sections encompassing 160 chapters. The first section highlights the mechanisms of the normal and abnormal mental function through evaluation of neuroproteins or the so-called 'think-proteins. This section describes the manifestations, clinical features, diagnosis, and therapeutic options of nervous system diseases. The second section tackles monoclonal proteins as a reagent to detect antigens. This section deals with the significant progress in cancer therapy and the binding of cytotoxic drugs to monoclonal antibodies. The third section considers the potential of isodalt electrophoresis and high-pressure liquid chromatography, with particular emphasis on their application to protein analysis in biological fluids. This book will be of great value to biochemists, clinical chemists, and clinicians.

Autoren/Hrsg.

Peeters, H.

Inhaltsverzeichnis

1;Front Cover;1
2;Protides of the Biological Fluids: Proceedings of the Thirtieth Colloquium, 1982;4
3;Copyright Page;5
4;Table of Contents;6
5;PREFACE;22
6;ACKNOWLEDGEMENTS;24
7;Part I: XXXth Anniversary Lecture;26
7.1;CHAPTER 1. 30 YEARS OF PROTIDES — AN ANNIVERSARY AND CHALLENGE;28
7.1.1;1. The scientific challenge;30
7.1.2;2. The major challenge;31
7.1.3;3. The most serious challenge;31
8;Part II: The Eleventh Arne Tiselius Memorial Lecture;32
8.1;CHAPTER 2. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY ON MATRICES OF AGAROSE;34
8.1.1;ABSTRACT;34
8.1.2;KEYWORDS;34
8.1.3;INTRODUCTION;34
8.1.4;SOME CHROMATOGRAPHIC CHARACTERISTICS OF AGAROSE;35
8.1.5;PREPARATION OF THE AGAROSE BEADS;36
8.1.6;THE DESIGN OF THE COLUMN TUBES;36
8.1.7;EXPERIMENTS AND RESULTS;37
8.1.8;DISCUSSION;41
8.1.9;ACKNOWLEDGEMENTS;41
8.1.10;REFERENCES;42
9;SECTION A: Neuroproteins;44
9.1;CHAPTER 3. CHEMICAL STRUCTURE AND MOLECULAR EVOLUTION OF S-100 PROTEINS;46
9.1.1;ABSTRACT;46
9.1.2;KEY WORDS;46
9.1.3;INTRODUCTION;46
9.1.4;MATERIALS AND METHODS;46
9.1.5;RESULTS AND DISCUSSION;46
9.1.6;REFERENCES;49
9.2;CHAPTER 4. SOME PROPERTIES OF S-100 PROTEIN IN SOLUTION;50
9.2.1;EXPERIMENTAL PROCEDURES;50
9.2.2;RESULTS AND DISCUSSION;51
9.2.3;REFERENCES;53
9.3;CHAPTER 5. THE RELATIONSHIP BETWEEN S-100 PROTEIN AND SPECIFIC SYNAPTOSOMAL COMPONENTS;54
9.3.1;EXPERIMENTAL PROCEDURES;54
9.3.2;RESULTS AND DISCUSSION;54
9.3.3;REFERENCES;57
9.3.4;SUMMARY;57
9.4;CHAPTER 6. IDENTIFICATION AND CHARACTERIZATION OF SULFHYDRYL-CONTAINING PROTEOLYTIC FRAGMENTS INVOLVED IN THE Ca-INDUCED CONFORMATIONAL CHANGE OF BEEF BRAIN S 100;58
9.4.1;ABSTRACT;58
9.4.2;KEYWORDS;58
9.4.3;INTRODUCTION;58
9.4.4;MATERIALS AND METHODS;59
9.4.5;RESULTS;60
9.4.6;DISCUSSION;65
9.4.7;ACKNOWLEDGMENT;67
9.4.8;REFERENCES;67
9.5;CHAPTER 7. THE S-100 ANTIGEN IN NON-NEURAL TISSUES;68
9.5.1;ABSTRACT;68
9.5.2;KEYWORDS;68
9.5.3;INTRODUCTION;68
9.5.4;EXPERIMENTAL PROCEDURES;69
9.5.5;RESULTS AND DISCUSSION;69
9.5.6;REFERENCES;71
9.6;CHAPTER 8. IMMUNOHISTOCHEMICAL LOCALIZATION OF NERVOUS TISSUE PROTEINS, S-100, GFAP AND ASTROPROTEIN IN EXTRANEURAL TISSUES;72
9.6.1;ABSTRACT;72
9.6.2;INTRODUCTION;72
9.6.3;MATERIALS AND METHODS;72
9.6.4;RESULTS;73
9.6.5;DISCUSSION;74
9.6.6;REFERENCES;75
9.7;CHAPTER 9. BRAIN SPECIFIC PROTEIN. SOME GENERAL REMARKS;76
9.7.1;ABSTRACT;76
9.7.2;INTRODUCTION;76
9.7.3;RESULTS;77
9.7.4;DISCUSSION;77
9.7.5;CONCLUSION;78
9.7.6;REFERENCES;78
9.8;CHAPTER 10. NEURON-SPECIFIC ENOLASE (NSE) IN BIOLOGICAL FLUIDS: A MARKER OF NEURONAL LESIONS;80
9.8.1;ABSTRACT;80
9.8.2;KEYWORDS;80
9.8.3;INTRODUCTION;80
9.8.4;MATERIALS AND METHODS;80
9.8.5;RESULTS AND DISCUSSION;81
9.8.6;ACKNOWLEDGEMENTS;85
9.8.7;REFERENCES;85
9.9;CHAPTER 11. RODENT ENOLASE CEREBRAL ISOZYMES AS DIFFERENTIATION MARKERS;86
9.9.1;Studies in the adult;86
9.9.2;Isozyme transitionsduring rodent forebrain differentiatior;87
9.9.3;Isozyme transitions during in vitro differentiation of neuroblastoma cells;87
9.9.4;Acknowledgements;89
9.9.5;References;89
9.10;CHAPTER 12. NEURON SPECIFIC ENOLASE IN BIOLOGICAL FLUIDS: A PROBE FOR NEURONAL AND NEUROENDOCRINE PATHOLOGY;90
9.10.1;ABSTRACT;90
9.10.2;KEYWORDS;90
9.10.3;INTRODUCTION;90
9.10.4;REFERENCES;94
9.11;CHAPTER 13. NEURON SPECIFIC ENOLASE — AN INDICATOR OF BRAIN DAMAGE DUE TO HYPOXIA IN NEWBORNS AND ADULTS;96
9.11.1;ABSTRACT;96
9.11.2;KEYWORDS;96
9.11.3;INTRODUCTION;96
9.11.4;MATERIAL AND METHODS;97
9.11.5;RESULTS AND DISCUSSION;97
9.11.6;REFERENCES;99
9.12;CHAPTER 14. CHARACTERIZATION OF THE D2-CELL ADHESION MOLECULE;100
9.12.1;ABSTRACT;100
9.12.2;KEY WORDS;100
9.12.3;INTRODUCTION;100
9.12.4;MATERIALS AND METHODS;100
9.12.5;RESULTS AND DISCUSSION;101
9.12.6;ACKNOWLEDGMENTS;103
9.12.7;REFERENCES;103
9.13;CHAPTER 15. A NEURONAL ADHESION MOLECULE IN THE CENTRAL NERVOUS SYSTEM: THE D2-PROTEIN;104
9.13.1;ABSTRACT;104
9.13.2;KEYWORDS;104
9.13.3;INTRODUCTION;104
9.13.4;D2-PR0TEIN DURING ONTOGENY;104
9.13.5;D2-PR0TEIN IN NEURITIC FASCICULATION;106
9.13.6;DISCUSSION;107
9.13.7;ACKNOWLEDGEMENT;107
9.13.8;REFERENCES;107
9.14;CHAPTER 16. PURIFICATION OF THE GLYCOPROTEIN D2 FROM FETAL AND ADULT HUMAN BRAIN;108
9.14.1;ABSTRACT;108
9.14.2;KEYWORDS;108
9.14.3;INTRODUCTION;108
9.14.4;MATERIALS AND METHODS;108
9.14.5;RESULTS AND DISCUSSION;109
9.14.6;ACKNOWLEDGMENT;111
9.14.7;REFERENCES;111
9.15;CHAPTER 17. DEVELOPMENTAL STUDY OF CHICK D2;112
9.15.1;ABSTRACT;112
9.15.2;KEYWORDS;112
9.15.3;INTRODUCTION;112
9.15.4;MATERIAL AND METHODS;112
9.15.5;RESULTS AND DISCUSSION;113
9.15.6;ACKNOWLEDGMENT;115
9.15.7;REFERENCES;115
9.16;CHAPTER 18. CHARACTERIZATION OF ANTIGENS OF THE CHOLINERGIC SYNAPSES IN THE ELECTRIC RAY TORPEDO MARMORATA;116
9.16.1;ABSTRACT;116
9.16.2;KEYWORDS;116
9.16.3;INTRODUCTION;116
9.16.4;MATERIALS AND METHODS;117
9.16.5;RESULTS AND DISCUSSION;117
9.16.6;ACKNOWLEDGEMENTS;119
9.16.7;REFERENCES;119
9.17;CHAPTER 19. A POSSIBLE PHYSIOLOGICAL ROLE OF ACETYLCHOLINE RECEPTOR ON MOUSE THYMOCYTES;120
9.17.1;ABSTRACT;120
9.17.2;KEYWORDS;120
9.17.3;INTRODUCTION;120
9.17.4;MATERIALS AND METHODS;121
9.17.5;RESULTS;121
9.17.6;DISCUSSION;121
9.17.7;ACKNOWLEDGEMENT;122
9.17.8;REFERENCES;122
9.18;CHAPTER 20. OLIGODENDROGLIAL, ASTROGLIAL AND GLIAL TUMOR-ASSOCIATED ANTIGENS DEFINED BY MONOCLONAL ANTIBODIES;124
9.18.1;ABSTRACT;124
9.18.2;KEYWORDS;124
9.18.3;INTRODUCTION;124
9.18.4;MONOCLONAL ANTIBODIES TO OLIGODENDROCYTES;125
9.18.5;A MONOCLONAL ANTIBODY TO RAT BRAIN ASTROCYTES;126
9.18.6;A MONOCLONAL ANTIBODY TO A GLIAL TUMOR ANTIGEN;127
9.18.7;REFERENCES;127
9.19;CHAPTER 21. POSTTRANSLATIONAL MODIFICATIONS OF MYELIN BASIC PROTEIN;128
9.19.1;ABSTRACT;128
9.19.2;KEYWORDS;128
9.19.3;REFERENCES;131
9.20;CHAPTER 22. "MYELIN-LIKE" OR PRE-MYELIN STRUCTURES IN CULTURES OF DISSOCIATED BRAIN CELLS FROM 14-15 DAY-OLD EMBRYONIC MICE;132
9.20.1;ABSTRACT;132
9.20.2;KEYWORDS;132
9.20.3;ABBREVIATIONS USED;132
9.20.4;INTRODUCTION;132
9.20.5;MATERIAL AND METHODS;133
9.20.6;RESULTS;133
9.20.7;DISCUSSION AND CONCLUSION;134
9.20.8;ACKNOWLEDGEMENT;135
9.20.9;REFERENCES;135
9.21;CHAPTER 23. IMMUNOHISTOCHEMISTRY AND RIA DETERMINATION OF MBP AS COMPLEMENTARY TOOLS TO STUDY MYELIN FORMATION IN THE CNS AND PNS OF MICE;136
9.21.1;Results;136
9.21.2;Discussion;138
9.21.3;Acknowledgements;138
9.21.4;References;138
9.22;CHAPTER 24. IMMUNOLOGIC REACTIVITY OF MYELIN BASIC PROTEIN (BP) IN INBRED GUINEA PIGS;140
9.22.1;ABSTRACT;140
9.22.2;KEYWORDS;140
9.22.3;REFERENCES;143
9.23;CHAPTER 25. MYELIN BASIC PROTEIN IN THE MLD MUTANT MOUSE DURING DEVELOPMENT;144
9.23.1;ABSTRACT;144
9.23.2;KEY WORDS;144
9.23.3;INTRODUCTION;144
9.23.4;RESULTS AND DISCUSSION;145
9.23.5;ACKNOWLEDGEMENT;147
9.23.6;REFERENCES;147
9.24;CHAPTER 26. GALACTOSYL- AND SULFOGALACTOSYL CERAMIDEAS CENTRAL NERVOUS TISSUE MARKERS;148
9.24.1;MATERIAL AND METHODS;148
9.24.2;RESULTS AND DISCUSSION;149
9.24.3;REFERENCES;151
9.25;CHAPTER 27. PURIFICATION OF A MEMBRANE GLYCOPROTEIN FROM FETAL HUMAN BRAIN;152
9.25.1;ABSTRACT;152
9.25.2;KEYWORDS;152
9.25.3;INTRODUCTION;152
9.25.4;MATERIALS AND METHODS;152
9.25.5;RESULTS AND DISCUSSION;154
9.25.6;ACKNOWLEDGMENT;155
9.25.7;REFERENCES;155
9.26;CHAPTER 28. CHARACTERIZATION OF HYALURONECTIN IN THE NERVOUS SYSTEM;156
9.26.1;ABSTRACT;156
9.26.2;KEYWORDS;156
9.26.3;INTRODUCTION;156
9.26.4;MATERIAL AND METHODS;156
9.26.5;RESULTS;157
9.26.6;DISCUSSION;159
9.26.7;ACKNOWLEDGEMENTS;159
9.26.8;REFERENCES;160
9.27;CHAPTER 29. TWO MARKERS FOR BRAIN TUMORS: GLIAL FIBRILLARY ACIDIC PROTEIN (GFA) AND HYALURONECTIN;162
9.27.1;ABSTRACT;162
9.27.2;KEYWORDS;162
9.27.3;INTRODUCTION;162
9.27.4;MATERIAL AND METHODS;162
9.27.5;RESULTS;163
9.27.6;DISCUSSION;163
9.27.7;ACKNOWLEDGEMENT;165
9.27.8;REFERENCES;165
9.28;CHAPTER 30. ACCESSIBILITY OF SULFHYDRYL GROUPS OF MYELIN FOLCH-PI PROTEIN;166
9.28.1;ABSTRACT;166
9.28.2;KEYWORDS;166
9.28.3;INTRODUCTION;166
9.28.4;MATERIAL AND METHODS;167
9.28.5;RESULTS AND DISCUSSION;167
9.28.6;CONCLUSION;169
9.28.7;ACKNOWLEDGEMENT;169
9.28.8;REFERENCES;169
9.29;CHAPTER 31. IMMUNOCHEMICAL AND IMMUNOHISTOLOGICAL STUDY OF CARBONIC ANHYDRASE IN THE RAT CNS;170
9.29.1;ABSTRACT;170
9.29.2;KEYWORDS;170
9.29.3;INTRODUCTION;170
9.29.4;METHODS;171
9.29.5;RESULTS AND DISCUSSION;171
9.29.6;REFERENCES;173
9.30;CHAPTER 32. IN VIVO AND IN VITRO STUDIES OF NEUROFILAMENT PROTEIN ASSEMBLY;174
9.30.1;ABSTRACT;174
9.30.2;KEY WORDS;174
9.30.3;INTRODUCTION;174
9.30.4;MATERIALS AND METHODS;175
9.30.5;RESULTS;176
9.30.6;DISCUSSION;178
9.30.7;ACKNOWLEDGEMENTS;179
9.30.8;REFERENCES;179
9.31;CHAPTER 33. BRAIN PROTEIN RESPONSES TO OPIATES;180
9.31.1;ABSTRACT;180
9.31.2;KEYWORDS;180
9.31.3;INTRODUCTION;180
9.31.4;ACKNOWLEDGEMENTS;183
9.31.5;REFERENCES;183
9.32;CHAPTER 34. ISOLATION AND PARTIAL BIOCHEMICAL CHARACTERIZATION OF A NOVEL POLYPEPTIDE FROM HUMAN CNS AND LIVER;184
9.32.1;INTRODUCTION;184
9.32.2;MATERIAL;184
9.32.3;RESULTS AND DISCUSSION;184
9.32.4;REFERENCES;187
9.33;CHAPTER 35. IDENTIFICATION OF NUCLEAR PROTEIN ANTIGENS OF RAT BRAIN;188
9.33.1;ABSTRACT;188
9.33.2;KEYWORDS;188
9.33.3;INTRODUCTION;188
9.33.4;EXPERIMENTAL PROCEDURES;189
9.33.5;RESULTS AND DISCUSSION;189
9.33.6;REFERENCES;191
9.34;CHAPTER 36. LOW ANGLE X-RAY DIFFRACTION STUDIES ON MYELIN ISOLATED FROM NORMAL HUMAN WHITE MATTER AND FROM PATIENTS DYING WITH MULTIPLE SCLEROSIS;192
9.34.1;ABSTRACT;192
9.34.2;KEY WORDS;192
9.34.3;INTRODUCTION;192
9.34.4;MATERIALS AND METHODS;193
9.34.5;RESULTS;193
9.34.6;DISCUSSION;194
9.34.7;ACKNOWLEDGEMENT;195
9.34.8;REFERENCES;195
9.35;CHAPTER 37. CENTRAL NERVOUS SYSTEM IMMUNOGLOBULINS (Ig) IN ADRENOLEUKODYSTROPHY (ALD);196
9.35.1;ABSTRACT;196
9.35.2;KEYWORDS;196
9.35.3;INTRODUCTION;196
9.35.4;MATERIALS AND METHODS;196
9.35.5;RESULTS AND CONCLUSIONS;197
9.35.6;ACKNOWLEDGEMENTS;198
9.35.7;REFERENCES;198
9.36;CHAPTER 38. EFFECT OF HUMAN FETAL ALPHAFETOPROTEIN ON EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS AND THE IMMUNE RESPONSE TO MYELIN ANTIGENS;200
9.36.1;ABSTRACT;200
9.36.2;KEYWORDS;200
9.36.3;INTRODUCTION;200
9.36.4;METHODS;201
9.36.5;RESULTS AND COMMENTS;202
9.36.6;REFERENCES;203
9.37;CHAPTER 39. IMMUNE REGULATION OF AUTOIMMUNE ENCEPHALOMYELITIS;204
9.37.1;ACKNOWLEDGEMENTS;207
9.37.2;REFERENCES;207
9.38;CHAPTER 40. IN VIVO DEMYELINATING ACTIVITY OF SERA FROM ANIMALS WITH CHRONIC RELAPSING EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS (Cr-EAE);208
9.38.1;ABSTRACT;208
9.38.2;KEYWORDS;208
9.38.3;INTRODUCTION;208
9.38.4;THE MODEL;208
9.38.5;CONTROL EXPERIMENTS;209
9.38.6;INCIDENCE OF DEMYELINATING ACTIVITY IN CR-EAE SERA;209
9.38.7;DISTRIBUTION OF DEMYELINATING LESIONS AND PATTERNS OF DEMYELINATION;210
9.38.8;MECHANISMS OF DEMYELINATION;210
9.38.9;CORRELATION BETWEEN DEMYELINATING ACTIVITY AND ANTIBODIES AGAINST GLYCOSPHINGOLIPIDS IN CR-EAE SERA;210
9.38.10;IMPLICATIONS FOR THE PATHOGENESIS OF CR-EAE;210
9.38.11;ACKNOWLEDGEMENT;211
9.38.12;REFERENCES;211
9.39;CHAPTER 41. "FAIL-SAFE" DETERMINANTS FOR IMMUNO-REGULATING AUTOIMMUNE DEMYELINATING DISEASES;212
9.39.1;INTRODUCTION;212
9.39.2;DISCUSSION;213
9.39.3;ACKNOWLEDGMENT;216
9.39.4;REFERENCES;216
9.40;CHAPTER 42. SERUM ANTIBODIES AGAINST CENTRAL NERVOUS SYSTEM (CNS) ANTIGENS IN CHRONIC RELAPSING EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS (CrEAE);218
9.40.1;ABSTRACT;218
9.40.2;KEY WORDS;218
9.40.3;INTRODUCTION;218
9.40.4;MATERIALS AND METHODS;219
9.40.5;RESULTS;219
9.40.6;DISCUSSION;220
9.40.7;ACKNOWLEDGEMENTS;221
9.40.8;REFERENCES;221
9.41;CHAPTER 43. "RECOVERY ASSOCIATED" SUPPRESSOR CELLS IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS (EAE): REPLACEMENT OF THEIR ACTIVITY IN VIVO BY CELL FREE EXTRACTS;222
9.41.1;INTRODUCTION;222
9.41.2;MATERIALS AND METHODS;222
9.41.3;RESULTS AND DISCUSSION;223
9.41.4;CONCLUSION;225
9.41.5;AKNOWLEDGEMENT;225
9.41.6;REFERENCES;225
9.42;CHAPTER 44. DEMONSTRATION OF SERUM IgG ANTIBODIES AGAINST MYELIN DURING THE COURSE OF RELAPSING EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS (r-EAE) IN GUINEA PIGS;226
9.42.1;ABSTRACT;226
9.42.2;INTRODUCTION;226
9.42.3;MATERIALS AND METHODS;226
9.42.4;RESULTS AND DISCUSSION;227
9.42.5;ACKNOWLEDGEMENT;229
9.42.6;REFERENCES;229
9.43;CHAPTER 45. STUDIES ON THE S-100 ANTIGEN IN CEREBROSPINAL FLUID OF NEUROLOGICAL PATIENTS;230
9.43.1;ABSTRACT;230
9.43.2;KEYWORDS;230
9.43.3;INTRODUCTION;230
9.43.4;MATERIALS AND METHODS;231
9.43.5;RESULTS AND DISCUSSION;231
9.43.6;REFERENCES;233
9.44;CHAPTER 46. DETERMINATION OF a-ALBUMIN (GFA) IN CEREBROSPINAL FLUID;234
9.44.1;ABSTRACT;234
9.44.2;KEYWORDS;234
9.44.3;INTRODUCTION;234
9.44.4;MATERIAL AND METHODS;234
9.44.5;RESULTS;235
9.44.6;CONCLUSIONS;237
9.44.7;REFERENCES;237
9.45;CHAPTER 47. CLINICAL APPLICATIONS OF HUMAN BRAIN-SPECIFIC PROTEIN MEASUREMENTS;238
9.45.1;ABSTRACT;238
9.45.2;KEYWORDS;238
9.45.3;INTRODUCTION;238
9.45.4;RADIOIMMUNOASSAY METHODS;238
9.45.5;CELLULAR LOCALIZATION OF HUMAN 'BRAIN-SPECIFIC' PROTEINS;240
9.45.6;CLINICAL MEASUREMENTS OF HUMAN 'BRAIN-SPECIFIC' PROTEINS;240
9.45.7;'BRAIN-SPECIFIC' PROTEINS IN NON-NERVOUS TISSUES;240
9.45.8;ACKNOWLEDGEMENT;241
9.45.9;REFERENCES;241
9.46;CHAPTER 48. THE DETERMINATION OF TRACE PROTEINS AND ANTI-MYELIN BASIC PROTEIN ANTIBODIES IN THE CEREBROSPINAL FLUID BY PARTICLE COUNTING IMMUNOASSAY;242
9.46.1;ABSTRACT;242
9.46.2;KEYWORDS;242
9.46.3;INTRODUCTION;242
9.46.4;DETERMINATION OF TRACE PROTEINS IN THE CSF : FERRITIN, IgM AND S-lOO;243
9.46.5;DETERMINATION OF ANTI-MYELIN BASIC PROTEIN (MBP) ANTIBODIES;245
9.46.6;ACKNOWLEDGEMENTS;246
9.46.7;REFERENCES;246
9.47;CHAPTER 49. RADIOIMMUNOLOGICAL DETERMINATION OF MYELIN BASIC PROTEIN IN THE CSF OF NEUROLOGICAL PATIENTS;248
9.47.1;ABSTRACT;248
9.47.2;KEY WORDS;248
9.47.3;INTRODUCTION;248
9.47.4;METHODS;249
9.47.5;RESULTS AND DISCUSSION;249
9.47.6;REFERENCES;251
9.48;CHAPTER 50. AN ENZYME IMMUNO ASSAY FOR THE DETECTION OF BASIC MYELIN PROTEIN AND ANTIBODIES TO BMP IN CSF;252
9.48.1;ABSTRACT;252
9.48.2;KEYWORDS;252
9.48.3;INTRODUCTION;252
9.48.4;MATERIALS;252
9.48.5;PROCEDURE;253
9.48.6;CONCLUSIONS;253
9.48.7;REFERENCES;254
9.49;CHAPTER 51. CSF AUTOANTIBODIES DETECT BRAIN ANTIGENS;256
9.49.1;ABSTRACT;256
9.49.2;KEYWORDS;256
9.49.3;INTRODUCTION;256
9.49.4;MATERIALS AND METHODS;256
9.49.5;RESULTS;257
9.49.6;DISCUSSION;259
9.49.7;ACKNOWLEDGEMENT;259
9.49.8;REFERENCES;259
9.50;CHAPTER 52. GALACTOCEREBROSIDE ANTIBODIES IN SERUM AND CEREBROSPINAL FLUID OF MULTIPLE SCLEROSIS AND BRAIN TUMOUR PATIENTS;260
9.50.1;ABSTRACT;260
9.50.2;KEYWORDS;260
9.50.3;INTRODUCTION;260
9.50.4;MATERIAL AND METHODS;260
9.50.5;RESULTS;261
9.50.6;DISCUSSION;262
9.50.7;ACKNOWLEDGEMENTS;263
9.50.8;REFERENCES;263
9.51;CHAPTER 53. DETERMINATION OF a1ACID GLYCOPROTEIN IN HUMAN CEREBROSPINAL FLUID BY AN IMMUNONEPHELOMETRIC ASSAY;264
9.51.1;ABSTRACT;264
9.51.2;KEYWORDS;264
9.51.3;INTRODUCTION;264
9.51.4;MATERIAL and METHODS;264
9.51.5;RESULTS and DISCUSSION;265
9.51.6;ACKNOWLEDGEMENT;267
9.51.7;REFERENCES;267
9.52;CHAPTER 54. DETERMINATION OF METHIONINE-ENKEPHALIN AND LEUCINE-ENKEPHALIN IN HUMAN CEREBROSPINAL FLUID;268
9.52.1;ABSTRACT;268
9.52.2;KEYWORDS;268
9.52.3;INTRODUCTION;268
9.52.4;MATERIAL and METHODS;268
9.52.5;RESULTS and DISCUSSION;269
9.52.6;REFERENCES;271
9.53;CHAPTER 55. DETERMINATION OF NEUROTENSIN IN HUMAN CEREBROSPINAL FLUID;272
9.53.1;ABSTRACT;272
9.53.2;KEYWORDS;272
9.53.3;INTRODUCTION;272
9.53.4;MATERIAL and METHODS;272
9.53.5;RESULTS and DISKUSSION;273
9.53.6;REFERENCES;275
9.54;CHAPTER 56. POLYACRYLAMIDE GEL ELECTROPHORESIS TECHNIQUE FOR THE SEPARATION OF HIGH MOLECULAR WEIGHT PROTEINS IN NATIVE CEREBROSPINAL FLUID AND SERUM;276
9.54.1;ABSTRACT;276
9.54.2;KEYWORDS;276
9.54.3;INTRODUCTION;276
9.54.4;MATERIAL AND METHODS;276
9.54.5;RESULTS AND DISCUSSION;278
9.54.6;ACKNOWLEDGEMENT;278
9.54.7;REFERENCES;279
9.55;CHAPTER 57. THE CORRELATION OF THE IgG PATTERNS OF CSF DETERMINED BY ISOELECTRIC FOCUSING WITH CLINICAL AND BIOCHEMICAL PARAMETERS OF MULTIPLE SCLEROSIS;280
9.55.1;ABSTRACT;280
9.55.2;KEYWORDS;280
9.55.3;INTRODUCTION;280
9.55.4;MATERIAL AND METHODS;280
9.55.5;RESULTS;282
9.55.6;DISCUSSION;283
9.55.7;REFERENCES;283
9.56;CHAPTER 58. DIRECT TISSUE ISOELECTRIC FOCUSING OF NERVOUS SYSTEM AND MUSCLE SECTIONS FOR DETECTION OF IgG PATTERNS;284
9.56.1;ABSTRACT;284
9.56.2;INTRODUCTION;284
9.56.3;MATERIALS AND METHODS;284
9.56.4;RESULTS;285
9.56.5;DISCUSSION;286
9.56.6;ACKNOWLEDGEMENT;286
9.56.7;REFERENCES;286
10;SECTION B: Monoclonal Antibodies;288
10.1;CHAPTER 59. A NEW HUMAN HYBRIDOMA SYSTEM (LICR-LON-HMy2) AND ITS USE IN THE PRODUCTION OF HUMAN MONOCLON ALANTIBODIES;290
10.1.1;THE BACKGROUND;290
10.1.2;THE PROBLEMS;290
10.1.3;THE ALTERNATIVES;293
10.1.4;THE FUTURE;293
10.1.5;ACKNOWLEDGEMENTS;293
10.1.6;REFERENCES;293
10.2;CHAPTER 60. PRODUCTION OF HUMAN ANTIBODIES OF PREDEFINED SPECIFICITY IN VITRO;294
10.2.1;ABSTRACT;294
10.2.2;KEYWORDS;294
10.2.3;INTRODUCTION;294
10.2.4;MATERIALS AND METHODS;295
10.2.5;RESULTS;295
10.2.6;DISCUSSION;296
10.2.7;REFERENCES;297
10.3;CHAPTER 61. HYBRIDOMAS GROWN IN SERUM-FREE MEDIUM;298
10.3.1;ABSTRACT;298
10.3.2;KEY WORDS;298
10.3.3;INTRODUCTION;298
10.3.4;MATERIALS AND METHODS;298
10.3.5;RESULTS AND DISCUSSION;299
10.3.6;ACKNOWLEDGEMENTS;302
10.3.7;REFERENCES;302
10.4;CHAPTER 62. STRATEGY TO OBTAIN MONOCLONAL ANTI-IDIOTYPE ANTIBODIES;304
10.4.1;ABSTRACT;304
10.4.2;KEYWORDS;304
10.4.3;INTRODUCTION;304
10.4.4;METHODS;305
10.4.5;RESULTS;305
10.4.6;CONCLUSION;306
10.4.7;ACKNOWLEDGEMENTS;306
10.4.8;REFERENCES;307
10.5;CHAPTER 63. MONOCLONAL ANTIBODIES AGAINST CARBOHYDRATE ANTIGENS;308
10.5.1;ABSTRACT;308
10.5.2;KEYWORDS;308
10.5.3;INTRODUCTION;308
10.5.4;CARBOHYDRATE DETERMINANTS RECOGNIZED BY MONOCLONAL ANTI-i AND ANTI-I ANTIBODIES;309
10.5.5;ANTI-I AND i ANTIBODIES AS REAGENTS;310
10.5.6;CARBOHYDRATE DETERMINANTS RECOGNIZED BY THE MOUSE HYBRIDOMA ANTIBODY ANTI-SSEA-1;310
10.5.7;ANTIGENS, I, i, AND SSEA-1 AS AN INTERRELATED SYSTEM OF CARBOHYDRATE DIFFERENTIATION ANTIGENS WHICH ALSO INVOLVES THE MAJOR BLOOD GROUP ANTIGENS ABH.;310
10.5.8;CAUTIONARY NOTE ON NATURAL ANTI-CARBOHYDRATE ANTIBODIES AS CONTAMINANTS OF HYBRIDOMA PRODUCTS;311
10.5.9;REFERENCES;311
10.6;CHAPTER 64. MULTIVALENT ANTIBODY RIA: A NEW ASSAY USING ONLY ANTIGEN FOR SCREENING HYBRIDOMA CULTURES;312
10.6.1;ABSTRACT;312
10.6.2;KEYWORDS;312
10.6.3;INTRODUCTION;312
10.6.4;MATERIAL AND METHODS;313
10.6.5;RESULTS;313
10.6.6;DISCUSSION;314
10.6.7;NOTE;314
10.6.8;ACKNOWLEDGEMENTS;314
10.6.9;REFERENCES;314
10.7;CHAPTER 65. A RADIO-IMMUNOBINDING METHOD ON GLUTARALDEHYDE-FIXED CELLS FOR THE SCREENING OF HYBRIDOMA SUPERNATANTS;316
10.7.1;ABSTRACT;316
10.7.2;KEYWORDS;316
10.7.3;INTRODUCTION;316
10.7.4;MATERIAL AND METHODS;316
10.7.5;RESULTS;317
10.7.6;DISCUSSION;318
10.7.7;ACKNOWLEDGEMENTS;319
10.7.8;REFERENCES;319
10.8;CHAPTER 66. SPECIFICITY SCREENING OF MONOCLON ALANTIBODIES OBTAINED AFTER IMMUNIZATION WITH A HUMAN MYELOMA CELL LINE;320
10.8.1;ABSTRACT;320
10.8.2;KEYWORDS;320
10.8.3;INTRODUCTION;320
10.8.4;METHODS;320
10.8.5;RESULTS AND DISCUSSION;321
10.8.6;ACKNOWLEDGEMENT;323
10.8.7;REFERENCES;323
10.9;CHAPTER 67. MONOCLONAL ANTIBODIES AND PRECIPITIN REACTIONS;324
10.9.1;ABSTRACT;324
10.9.2;KEYWORDS;324
10.9.3;INTRODUCTION;324
10.9.4;DESCRIPTION OF THE TWO STAGE MODEL;324
10.9.5;RESULTS OF COMPUTER SIMULATION;325
10.9.6;DISCUSSION;327
10.9.7;REFERENCES;327
10.10;CHAPTER 68. DETERMINATION OF AFFINITY AND CONCENTRATION OF MONOCLONAL ANTIBODIES IN ASCITIC FLUIDS;328
10.10.1;ABSTRACT;328
10.10.2;KEYWORDS;328
10.10.3;INTRODUCTION;328
10.10.4;MATERIALS AND METHODS;328
10.10.5;RESULTS AND DISCUSSION;329
10.10.6;REFERENCES;331
10.11;CHAPTER 69. MONOCLONAL MURINE ANTIBODIES REACTIVE WITH CELL NUCLEI;332
10.11.1;ABSTRACT;332
10.11.2;KEYWORDS;332
10.11.3;INTRODUCTION;332
10.11.4;MATERIALS AND METHODS;332
10.11.5;RESULTS;333
10.11.6;DISCUSSION;333
10.11.7;REFERENCES;335
10.12;CHAPTER 70. MONOCLONAL ANTIBODIES WITH DUAL ANTIGEN SPECIFICITY;336
10.12.1;ABSTRACT;336
10.12.2;KEY WORDS;336
10.12.3;TEXT;336
10.12.4;ACKNOWLEDGEMENTS;340
10.12.5;REFERENCES;341
10.13;CHAPTER 71. MONOCLONAL ANTIBODIES TO CELL SURFACE ANTIGENS OF MOUSE BLADDER CARCINOMAS;342
10.13.1;ABSTRACT;342
10.13.2;INTRODUCTION;342
10.13.3;RESULTS;343
10.13.4;DISCUSSION;344
10.13.5;ACKNOWLDGEMENTS;344
10.13.6;REFERENCES;344
10.14;CHAPTER 72. STRUCTURAL STUDIES OF HUMAN MELANOMA-ASSOCIATED ANTIGENp97;346
10.14.1;ABSTRACT;346
10.14.2;MONOCLONAL ANTIBODIES TO p97;346
10.14.3;TISSUE DISTRIBUTION OF p97;346
10.14.4;STRUCTURAL STUDIES OF p97;347
10.14.5;DISCUSSION;348
10.14.6;ACKNOWLEDGEMENTS;348
10.14.7;REFERENCES;348
10.15;CHAPTER 73. CELL SURFACE ANTIGENS OF HUMAN MELANOMA;350
10.15.1;ABSTRACT;350
10.15.2;INTRODUCTION;350
10.15.3;RESULTS;350
10.15.4;DISCUSSION;351
10.15.5;ACKNOWLEDGEMENTS;352
10.15.6;REFERENCES;352
10.16;CHAPTER 74. A DOUBLE DETERMINANT IMMUNOASSAY (DDIA) WITH MONOCLONAL ANTIBODIES TO A HUMAN HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN (HMW-MAA);354
10.16.1;ABSTRACT;354
10.16.2;INTRODUCTION;354
10.16.3;MATERIALS AND METHODS;354
10.16.4;RESULTS AND DISCUSSION;354
10.16.5;References;357
10.16.6;Acknowledgements;357
10.17;CHAPTER 75. IMMUNOLOGICAL STUDIES ON MEMBRANE ASSOCIATED ANTIGENS FROM RENAL ADENOCARCINOMA AND HUMAN KIDNEY CORTEX USING POLY- AND MONOCLONAL ANTIBODIES;358
10.17.1;INTRODUCTION;358
10.17.2;MATERIAL AND METHODS;358
10.17.3;RESULTS AND DISCUSSION;359
10.17.4;REFERENCES;361
10.18;CHAPTER 76. MALIGNIN, ANTI-MALIGNIN ANTIBODY AND SCANTAG;362
10.18.1;ABSTRACT;362
10.18.2;KEYWORDS;362
10.18.3;INTRODUCTION;363
10.18.4;PATIENTS, MATERIALS AND METHODS;363
10.18.5;RESULTS - HUMAN SERUM ANTIBODY STUDIES;367
10.18.6;DISCUSSION - HUMAN SERUM ANTIBODY STUDIES;370
10.18.7;CONFIRMATORY STUDIES ON HUMAN SERUM ANTIBODY STUDIES;371
10.18.8;IN VIVO DETECTION OE CANCER CELLS WITH RADIOISOTOPE SIGNAL FROM SCANTAG;372
10.18.9;MONOCLONAL ANTI-MALIGNIN ANTIBODIES;374
10.18.10;DEMONSTRATION BY CYTOFLQOROGRAPHY OF A DIAGNOSTIC "MALIGNIN FLUORESCENT INDEX" WITH MONOCLONAL ANTI-MALIGNIN ANTIBODIES F & S;375
10.18.11;DISCUSSION;376
10.18.12;ACKNOWLEDGEMENTS;376
10.18.13;REFERENCES;377
10.19;CHAPTER 77. RESULTS OF EARLY TRIALS USING MURINE MONOCLONAL ANTIBODIES AS ANTICANCER THERAPY;378
10.19.1;ABSTRACT;378
10.19.2;KEY WORDS;378
10.19.3;INTRODUCTION;378
10.19.4;MATERIALS AND METHODS;378
10.19.5;RESULTS;380
10.19.6;DISCUSSION;381
10.19.7;ACKNOWLEDGEMENT;382
10.19.8;REFERENCES;383
10.20;CHAPTER 78. HIGH EFFICIENCY OF IMMUNOTOXIN POTENTIATED BY LYSOSOMOTROPIC AMINES TO SPECIFICALLY KILL TUMOR CELLS;384
10.20.1;ABSTRACT;384
10.20.2;KEYWORDS;384
10.20.3;INTRODUCTION;384
10.20.4;MATERIAL AND METHODS;385
10.20.5;RESULTS AND DISCUSSION;385
10.20.6;REFERENCES;388
10.21;CHAPTER 79. IN VIVO EFFECT OF THE CONJUGATE OF MONOCLONAL ANTIBODY WITH CYTOTOXIC AGENT ON THE TUMOR GROWTH OF HUMAN MELANOMA;390
10.21.1;ABSTRACT;390
10.21.2;KEY WORDS;390
10.21.3;INTRODUCTION;390
10.21.4;MATERIALS AND METHODS;390
10.21.5;RESULTS AND DISCUSSION;391
10.21.6;ACKNOWLEDGEMENTS;393
10.21.7;REFERENCES;393
10.22;CHAPTER 80. MONOCLONAL ANTIBODIES AGAINST HUMAN GASTRIC CARCINOMAS;394
10.22.1;ABSTRACT;394
10.22.2;KEYWORDS;394
10.22.3;INTRODUCTION;394
10.22.4;MATERIALS AND METHODS;394
10.22.5;RESULTS AND DISCUSSION;395
10.22.6;ACKNOWLEDGEMENTS;398
10.22.7;REFERENCES;398
10.23;CHAPTER 81. MONOCLONAL ANTIBODIES FOR TARGETED THERAPY WITH VINDESINE;400
10.23.1;ABSTRACT;400
10.23.2;KEYWORDS;400
10.23.3;INTRODUCTION;400
10.23.4;MATERIALS AND METHODS;400
10.23.5;RESULTS;401
10.23.6;DISCUSSION;404
10.23.7;ACKNOWLEDGEMENTS;404
10.23.8;REFERENCES;404
10.24;CHAPTER 82. DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF A MONOCLONAL ANTIBODY AGAINST HUMAN OSTEOGENIC SARCOMA;406
10.24.1;ABSTRACT;406
10.24.2;INTRODUCTION;406
10.24.3;REFERENCES;411
10.25;CHAPTER 83. IDENTIFICATION OF HUMAN BLOOD PLATELET MEMBRANE CONGENITAL DEFECTS BY THE USE OF MONOCLONAL ANTIBODIES;412
10.25.1;ABSTRACT;412
10.25.2;KEYWORDS;412
10.25.3;INTRODUCTION;412
10.25.4;MATERIALS AND METHODS;413
10.25.5;RESULTS;413
10.25.6;DISCUSSION;414
10.25.7;ACKNOWLEDGMENTS;415
10.25.8;REFERENCES;415
10.26;CHAPTER 84. EVIDENCE THAT THE MONOCLONAL ANTIBODY AN 51 IS DIRECTED AGAINST PLATELET MEMBRANE GLYCOPROTEIN lb;416
10.26.1;ABSTRACT;416
10.26.2;KEYWORDS;416
10.26.3;INTRODUCTION;416
10.26.4;METHODS;418
10.26.5;RESULTS AND DISCUSSION;418
10.26.6;REFERENCES;418
10.27;CHAPTER 85. MONOCLONAL ANTIBODIES TO PROTHROMBIN: A STUDY OF THEIR SPECIFICITIES FOR THE DIFFERENT PROTHROMBIN ACTIVATION PRODUCTS;420
10.27.1;ABSTRACT;420
10.27.2;KEYWORDS;420
10.27.3;INTRODUCTION;420
10.27.4;MATERIALS and METHODS;421
10.27.5;RESULTS;421
10.27.6;DISCUSSION;423
10.27.7;ACKNOWLEDGMENTS;423
10.27.8;REFERENCES;423
10.28;CHAPTER 86. MONOCLONAL ANTIBODIES FOR DOMAINS WHICH ARE DIFFERENTIALLY EXPRESSEDIN FIBRINOGEN, IN FIBRINOGEN DEGRADATION PRODUCTS OR IN FIBRIN DEGRADATION PRODUCTS;424
10.28.1;MATERIAL AND METHODS;424
10.28.2;RESULTS;426
10.28.3;DISCUSSION;426
10.28.4;ACKNOWLE DGE MENT;427
10.28.5;REFERENCES;427
10.29;CHAPTER 87. AFFINITY DEPLETION AND AFFINITY PURIFICATION OF HUMAN FACTOR IX BY MONOCLONAL ANTIBODIES;428
10.29.1;ABSTRACT;428
10.29.2;KEYWORDS;428
10.29.3;INTRODUCTION;428
10.29.4;MATERIALS AND METHODS;429
10.29.5;RESULTS;429
10.29.6;DISCUSSION;431
10.29.7;REFERENCES;432
10.30;CHAPTER 88. MONOCLONAL ANTIBODIES IN ANALYSIS OF TRYPSIN DIGESTED PROTEOLYTIC FRAGMENTS OF HUMAN PLASMA FIBRONECTIN;434
10.30.1;ABSTRACT;434
10.30.2;INTRODUCTION;434
10.30.3;MATERIALS AND METHODS;435
10.30.4;RESULTS AND DISCUSSION;435
10.30.5;ACKNOWLEDGEMENTS;436
10.30.6;REFERENCES;436
10.30.7;FIGURE LEGENDS;436
10.31;CHAPTER 89.
MONOCLONAL ANTIBODIES DIFFERENTIATING A SUBTYPE OF LEUKEMIAS;438
10.31.1;ABSTRACT;438
10.31.2;KEYWORDS;438
10.31.3;INTRODUCTION;438
10.31.4;MATERIALS AND METHODS;438
10.31.5;RESULTS;439
10.31.6;DISCUSSION;439
10.31.7;ACKNOWLEDGEMENT;440
10.31.8;REFERENCES;440
10.32;CHAPTER 90.
CLINICAL UTILITY OF MONOCLONAL ANTIBODIES IN THE PHENOTYPING OF ACUTE AND CHRONIC LYMPHOCYTIC LEUKEMIA;442
10.32.1;ABSTRACT;442
10.32.2;KEY WORDS;442
10.32.3;INTRODUCTION;442
10.32.4;METHODS;443
10.32.5;RESULTS;443
10.32.6;SUMMARY;446
10.32.7;ACKNOWLEDGEMENTS;446
10.32.8;REFERENCES;446
10.33;CHAPTER 91.
LEUKEMIA DIAGNOSIS WITH MONOCLONAL ANTIBODIES;448
10.33.1;SUMMARY;448
10.33.2;KEY WORDS;448
10.33.3;INTRODUCTION;448
10.33.4;MATERIALS AND METHODS;449
10.33.5;RESULTS AND DISCUSSION;449
10.33.6;REFERENCES;453
10.34;CHAPTER 92.
MONOCLONAL ANTIBODIES TO HUMAN MYELOID ASSOCIATED ANTIGENS;454
10.34.1;ABSTRACT;454
10.34.2;KEY WORDS;454
10.34.3;INTRODUCTION;454
10.34.4;MATERIALS AND METHODS;455
10.34.5;RESULTS AND CONCLUSION;455
10.34.6;ACKNOWLEDGEMENT;457
10.34.7;REFERENCES;457
10.35;CHAPTER 93.
CHARACTERIZATION OF A MURINE MONOCLONAL ANTIBODY SPECIFIC FOR EARLY LYMPHOHEMOPOIETIC CELLS;458
10.35.1;ABSTRACT;458
10.35.2;KEYWORDS;458
10.35.3;INTRODUCTION;458
10.35.4;MATERIALS and METHODS;458
10.35.5;RESULTS;459
10.35.6;DISCUSSION;459
10.35.7;ACKNOWLEDGEMENT;461
10.35.8;REFERENCES;461
10.36;CHAPTER 94.
UNEXPECTED SPECIFICITIES OF MONOCLONAL ANTIBODIES;462
10.36.1;ABSTRACT;462
10.36.2;KEYWORDS;462
10.36.3;INTRODUCTION;462
10.36.4;METHODS;462
10.36.5;RESULTS;463
10.36.6;DISCUSSION;465
10.36.7;REFERENCES;465
10.37;CHAPTER 95.
IN SITU ANALYSIS OF MONONUCLEAR CELL INFILTRATE IN LIVER BIOPSIES OF PATIENTS WITH ORTHOTOPIC LIVER TRANSPLANTA TION;466
10.37.1;ABSTRACT;466
10.37.2;KEYWORDS;466
10.37.3;INTRODUCTION;466
10.37.4;MATERIAL AND METHODS;466
10.37.5;RESULTS;467
10.37.6;DISCUSSION;467
10.37.7;REFERENCES;468
10.38;CHAPTER 96.
T LYMPHOCYTES IN THE HUMAN FETUS, STUDIED WITH MONOCLONAL ANTIBODIES;470
10.38.1;ABSTRACT;470
10.38.2;KEYWORDS;470
10.38.3;INTRODUCTION;470
10.38.4;MATERIAL AND METHODS;470
10.38.5;RESULTS;471
10.38.6;DISCUSSION;473
10.38.7;ACKNOWLEDGEMENT;474
10.38.8;REFERENCES;474
10.39;CHAPTER 97.
A MONOCLONAL ANTIBODY DIRECTED AGAINST HLA-DR MOLECULES INHIBITS THE INTERLEUKIN-2-DEPENDENT T CELL PROLIFERATION IN HUMANS;476
10.39.1;INTRODUCTION;476
10.39.2;MATERIALS AND METHODS;476
10.39.3;RESULTS AND DISCUSSION;477
10.39.4;REFERENCES;479
10.40;CHAPTER 98.
SURFACE PHENOTYPE OF HELPER AND SUPPRESSOR HUMAN T CELL CLONES;480
10.40.1;INTRODUCTION;480
10.40.2;MATERIALS AND METHODS;480
10.40.3;RESULTS AND DISCUSSION;482
10.40.4;REFERENCES;484
10.41;CHAPTER 99.
T-LYMPHOCYTE SUBPOPULATIONS IN PERIPHERAL BLOOD OF LONG-SURVIVORS WITH HODGKIN'S DISEASE OFF-THERAPY: DETERMINATIONS BY MEANS OF MONOCLONAL ANTIBODIES;486
10.41.1;ABSTRACT;486
10.41.2;KEYWORDS;486
10.41.3;INTRODUCTION;486
10.41.4;RESULTS;487
10.41.5;AKNOWLEDGEMENT;489
10.41.6;REFERENCES;489
10.42;CHAPTER 100.
HUMAN BLOOD T-CELL SUBPOPULATIONS IDENTIFIED BY MONOCLONAL ANTIBODIES IN AGEING;490
10.42.1;ABSTRACT;490
10.42.2;KEYWORDS;490
10.42.3;INTRODUCTION;490
10.42.4;MATERIALS AND METHODS;490
10.42.5;RESULTS AND DISCUSSION;491
10.42.6;ACKNOWLEDGEMENTS;493
10.42.7;REFERENCES;493
10.43;CHAPTER 101.
MOUSE HYBRIDOMA LINES SPECIFIC FOR GENETIC MARKERS OF THE RABBIT IMMUNOGLOBULINS (ALLOTYPES);494
10.43.1;ABSTRACT;494
10.43.2;KEYWORDS;494
10.43.3;INTRODUCTION;494
10.43.4;DESCRIPTION OF THE METHODS AND GENERAL STRATEGY;495
10.43.5;CHARACTERIZATION OF THE HYBRIDOMA PRODUCT;496
10.43.6;ACKNOWLEDGEMENT;497
10.43.7;REFERENCES;497
10.44;CHAPTER 102.
MONOCLONAL ANTI-ALLOTYPE ANTIBODIES AS PROBES FOR THE RABBIT T-CELL RECEPTOR;498
10.44.1;ABSTRACT;498
10.44.2;KEYWORDS;498
10.44.3;INTRODUCTION;498
10.44.4;RESULTS AND DISCUSSION;499
10.44.5;ACKNOWLEDGEMENTS;501
10.44.6;REFERENCES;501
10.45;CHAPTER 103.
MONOCLONAL ANTIBODIES AGAINST Ia +, ANTIGEN SPECIFIC T CELL FACTORS;502
10.45.1;ABSTRACT;502
10.45.2;INTRODUCTION;502
10.45.3;MATERIALS AND METHODS;502
10.45.4;RESULTS;503
10.45.5;DISCUSSION;503
10.45.6;ACKNOWLEDGEMENTS;504
10.45.7;REFERENCES;504
10.46;CHAPTER 104.
MONOCLONAL ANTI-IMMUNOGLOBULIN REAGENTS IN THE DETECTION OF IMMUNOGLOBULIN ON THE SURFACE OF NORMAL AND NEOPLASTIC B LYMPHOCYTES;508
10.46.1;ABSTRACT;508
10.46.2;INTRODUCTION;508
10.46.3;RESULTS;510
10.46.4;ACKNOWLEDGMENTS;511
10.46.5;REFERENCES;511
10.47;CHAPTER 105.
ANALYSIS OF HUMAN B CELL MEMBRANE ANTIGENS BY MEANS OF MONOCLONAL ANTIBODIES;512
10.47.1;ABSTRACT;512
10.47.2;KEYWORDS;512
10.47.3;INTRODUCTION;512
10.47.4;MATERIAL AND METHODS;512
10.47.5;DISCUSSION;515
10.47.6;ACKNOWLEDGMENTS;515
10.47.7;REFERENCES;515
10.48;CHAPTER 106.
MONOCLONAL ANTIBODIES TO HUMAN LEUKOCYTE AND FIBROBLAST INTERFERON;516
10.48.1;ABSTRACT;516
10.48.2;KEYWORDS;516
10.48.3;INTRODUCTION;516
10.48.4;MATERIALS AND METHODS;517
10.48.5;RESULTS AND DISCUSSION;517
10.48.6;REFERENCES;519
10.49;CHAPTER 107.
MONOCLONAL ANTIBODIES AGAINST HUMAN LEUCOCYTE INTERFERONS FOR THE DEFINITION OF SUBCLASSES AND THEIR AFFINITY PURIFICATION;520
10.49.1;ABSTRACT;520
10.49.2;KEYWORDS;520
10.49.3;INTRODUCTION;520
10.49.4;MATERIALS AND METHODS;521
10.49.5;RESULTS AND DISCUSSION;521
10.49.6;ACKNOWLEDGEMENTS;523
10.49.7;REFERENCES;523
10.50;CHAPTER 108.
MONOCLONAL ANTIBODIES TO HEPATITIS ANTIGENS AS DIAGNOSTIC TOOLS;524
10.50.1;ABSTRACT;524
10.50.2;INTRODUCTION;524
10.50.3;MATERIALS AND METHODS;524
10.50.4;RESULTS;525
10.50.5;DISCUSSION;527
10.50.6;ACKNOWLEDGEMENTS;527
10.50.7;REFERENCES;527
10.51;CHAPTER 109.
AFFINITY PURIFICATION OF HEPATITIS B SURFACE ANTIGEN USING RF-HBs-1 MONOCLONAL ANTIBODY;530
10.51.1;ABSTRACT;530
10.51.2;KEYWORDS;530
10.51.3;INTRODUCTION;530
10.51.4;MATERIALS AND METHODS;530
10.51.5;RESULTS;531
10.51.6;DISCUSSION;532
10.51.7;ACKNOWLEDGEMENTS;533
10.51.8;REFERENCES;533
10.52;CHAPTER 110.
A SEROLOGICAL TEST FOR TUBERCULOSIS BASED ON MURINE MONOCLONAL ANTIBODIES;534
10.52.1;ABSTRACT;534
10.52.2;KEYWORDS;534
10.52.3;INTRODUCTION;534
10.52.4;MATERIALS AND METHODS;535
10.52.5;RESULTS AND DISCUSSION;536
10.52.6;REFERENCES;537
10.53;CHAPTER 111.
MONOCLONAL ANTIBODIES TO POLIOVIRUS AND ITS CAPSID PROTEINS;538
10.53.1;ABSTRACT;538
10.53.2;RESULTS;538
10.53.3;DISCUSSION;540
10.53.4;REFERENCES;540
10.54;CHAPTER 112.
PRODUCTION AND USE OF MONOCLONAL ANTIBODIES TO POLIOVIRUSES;542
10.54.1;ABSTRACT;542
10.54.2;KEYWORDS;542
10.54.3;INTRODUCTION;542
10.54.4;MATERIALS AND METHODS;542
10.54.5;RESULTS AND DISCUSSION;543
10.54.6;ACKNOWLEDGEMENTS;545
10.54.7;REFERENCES;545
10.55;CHAPTER 113.
MONOCLONAL ANTIBODIES AND DIAGNOSIS OF SCHISTOSOMIASIS IN MAN;546
10.55.1;ABSTRACT;546
10.55.2;INTRODUCTION;546
10.55.3;EXPERIMENTAL AND RESULTS;546
10.55.4;ACKNOWLEDGEMENTS;549
10.55.5;REFERENCES;549
10.56;CHAPTER 114.
MONOCLONAL ANTIBODIES TO MYELIN BASIC PROTEIN;550
10.56.1;ABSTRACT;550
10.56.2;KEYWORDS;550
10.56.3;INTRODUCTION;550
10.56.4;MATERIALS AND METHODS;551
10.56.5;RESULTS AND DISCUSSION;551
10.56.6;ACKNOWLEDGMENTS;553
10.56.7;REFERENCES;553
10.57;CHAPTER 115.
MONOCLONAL ANTIBODIES AS PROBES FOR NEURAL CELL-SURFACE GLYCOPROTEINS;554
10.57.1;ABSTRACT;554
10.57.2;KEYWORDS;554
10.57.3;INTRODUCTION;554
10.57.4;GENERATION OF HYBRIDOMAS;554
10.57.5;CONCLUSION;558
10.57.6;ACKNOWLEDGEMENT;559
10.57.7;REFERENCES;559
10.58;CHAPTER 116. ULTRASTRUCTURAL IMMUNO HISTOCHEMICALSTUDY OF NERVE CELL SURFACE ANTIGENS WITH MONOCLONAL ANTIBODIES;560
10.58.1;ABSTRACT;560
10.58.2;KEYWORDS;560
10.58.3;INTRODUCTION;560
10.58.4;METHODS;561
10.58.5;RESULTS AND DISCUSSION;561
10.58.6;REFERENCES;563
10.59;CHAPTER 117.
MONOCLONAL ANTIBODIES AGAINST GLIAL FIBRILLARY ACIDIC PROTEIN;564
10.59.1;ABSTRACT;564
10.59.2;KEYWORDS;564
10.59.3;INTRODUCTION;564
10.59.4;MATERIALS AND METHODS;565
10.59.5;RESULTS AND DISCUSSION;565
10.59.6;ACKNOWLEDGEMENTS;567
10.59.7;REFERENCES;567
10.60;CHAPTER 118.
MONOCLONAL ANTIBODIES IN SIMULTANEOUS MARKING ELISA SYSTEMS;568
10.60.1;ABSTRACT;568
10.60.2;KEYWORDS;568
10.60.3;INTRODUCTION;568
10.60.4;MATERIALS AND METHODS;569
10.60.5;RESULTS AND DISCUSSION;569
10.60.6;CONCLUSION;571
10.60.7;REFERENCES;571
10.61;CHAPTER 119.
ADVANTAGES AND DISADVANTAGES IN THE APPLICATION OF MONOCLONAL ANTIBODIES AS TOOLS IN CLINICAL DIAGNOSIS — MONOCLONAL ANTLHCG IN IMMUNOASSAY SYSTEMS;574
10.61.1;ABSTRACT;574
10.61.2;KEYWORDS;574
10.61.3;ABBREVIATIONS;574
10.61.4;INTRODUCTION;574
10.61.5;RESULTS AND DISCUSSION;575
10.61.6;CONCLUSIONS;577
10.61.7;ACKNOWLEDGEMENTS;577
10.61.8;REFERENCES;578
10.62;CHAPTER 120.
PRODUCTION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES SPECIFIC FOR PARATHORMONE;580
10.62.1;ABSTRACT;580
10.62.2;KEYWORDS;580
10.62.3;INTRODUCTION;580
10.62.4;METHODS;581
10.62.5;RESULTS;581
10.62.6;REFERENCES;582
10.63;CHAPTER 121.
IMMUNOGENIC AND ANTIGENIC EPITOPES OF IMMUNOGLOBULINS VI. APPLICATION OF MONOCLONAL ANTIBODIES TO HUMAN IgG SUB-CLASSES IN QUANTITATIVE ASSAYS;584
10.63.1;REFERENCES;587
10.64;CHAPTER 122.
MONOCLONAL ANTIBODIES AGAINST Ml ANTIGEN, A FUCOMUCIN OF THE HUMAN GASTROINTESTINAL MUCOSA;588
10.64.1;ABSTRACT;588
10.64.2;KEYWORDS;588
10.64.3;INTRODUCTION;588
10.64.4;MATERIALS AND METHODS;588
10.64.5;RESULTS;589
10.64.6;DISCUSSION;591
10.64.7;REFERENCES;591
10.65;CHAPTER 123. STUDY OF THE DISSOCIATION CONSTANT OF FOUR MONOCLONAL HYBRIDOMA ANTIBODIES SPECIFIC TO HUMAN ß2 MICROGLOBULIN. EFFECT OF 2 MERCAPTO-ETHANOL ON THEIR ACTIVITY;592
10.65.1;INTRODUCTION;592
10.65.2;MATERIALS AND METHODS;592
10.65.3;RESULTS AND DISCUSSION;593
10.65.4;CONCLUSION;595
10.65.5;REFERENCES;595
10.66;CHAPTER 124.
TWO MONOCLONAL ANTIBODIES AGAINST HUMAN CARDIAC MYOSINS;596
10.66.1;ABSTRACT;596
10.66.2;KEYWORDS;596
10.66.3;INTRODUCTION;597
10.66.4;REFERENCES;599
10.67;CHAPTER 125.
DEVELOPMENT OF A SCREENING SYSTEM FOR THE DETECTION OF SOMATIC MUTATIONS: DETECTION OF MONOCLONAL ANTIBODIES SPECIFIC FOR HEMOGLOBIN DETERMINANTS;600
10.67.1;ABSTRACT;600
10.67.2;KEYWORDS;600
10.67.3;INTRODUCTION;600
10.67.4;MATERIAL ANDMEIBODS;600
10.67.5;ENZYME IMMUNOASSAY;601
10.67.6;RESULTS;601
10.67.7;DISCUSSION;603
10.67.8;REFERENCES;603
11;SECTION C: Separation Methods;604
11.1;CHAPTER 126.
METHODS OF TWO-DIMENSIONAL GEL ELECTROPHORESIS FOR THE CLINICAL LABORATORY;606
11.1.1;ABSTRACT;606
11.1.2;KEY WORDS;606
11.1.3;1. INTRODUCTION;606
11.1.4;2. THE HOSPITAL-BASED 2DGE1 LABORATORY;606
11.1.5;3. SAMPLE PREPARATION FOR SILVER STAINED GELS;608
11.1.6;4. IEF GRADIENTS;610
11.1.7;5. SDS-PAGE GRADIENTS;610
11.1.8;6. VISUALIZATION;610
11.1.9;7. CONCLUSIONS;610
11.1.10;ACKNOWLEDGEMENTS;611
11.1.11;REFERENCES;611
11.2;CHAPTER 127.
THE DEMONSTRATION OF HUMAN BRAIN-SPECIFIC SOLUBLE PROTEINS USING HIGH RESOLUTION TWO-DIMENSIONAL POLYACRYLAMIDE GEL ELECTROPHORESIS;612
11.2.1;ABSTRACT;612
11.2.2;KEYWORDS;612
11.2.3;INTRODUCTION;612
11.2.4;MATERIALS AND METHODS;613
11.2.5;RESULTS AND DISCUSSION;613
11.2.6;ACKNOWLEDGEMENT;615
11.2.7;REFERENCES;615
11.3;CHAPTER 128.
BRAIN PROTEINS IN SOLUBLE AND INSOLUBLE FRACTIONS ANALYZED BY MICRO TWO-DIMENSIONALELECTROPHORESIS;616
11.3.1;ABSTRACT;616
11.3.2;KEYWORDS;616
11.3.3;INTRODUCTION;616
11.3.4;MATERIALS AND METHODS;617
11.3.5;RESULTS AND DISCUSSION;617
11.3.6;REFERENCES;619
11.4;CHAPTER 129.
DEMONSTRATION OF PREALBUMIN, APOLIPOPROTEIN A I AND 7-S-BETA1- GLOBULIN FROM HUMAN BLOOD BY DOUBLE ONE-DIMENSIONAL ELECTROPHORESIS;620
11.4.1;ABSTRACT;620
11.4.2;KEYWORDS;620
11.4.3;INTRODUCTION;620
11.4.4;METHODS AND RESULTS;621
11.4.5;ACKNOWLEDGEMENT;623
11.4.6;REFERENCES;623
11.5;CHAPTER 130.
IMMOBILIZED pH GRADIENTS FOR ISOELECTRIC FOCUSING. I: THEORY AND METHODOLOGY;624
11.5.1;SUMMARY;624
11.5.2;KEYWORDS;624
11.5.3;INTRODUCTION;624
11.5.4;THEORY AND METHODOLOGY;624
11.5.5;REFERENCES;627
11.5.6;ACKNOWLEDGEMENTS;627
11.6;CHAPTER 131.
ISOELECTRIC FOCUSING IN IMMOBILIZED pH GRADIENTS. II: APPLICATION TO HEMOGLOBIN ANALYSIS;628
11.6.1;SUMMARY;628
11.6.2;KEYWORDS;628
11.6.3;INTRODUCTION;628
11.6.4;EXPERIMENTAL;628
11.6.5;RESULTS AND DISCUSSION;630
11.6.6;REFERENCES;631
11.6.7;ACKNOWLEDGEMENTS;631
11.7;CHAPTER 132.
ISOELECTRIC FOCUSING IN IMMOBILIZED pH-GRADIENTS. III. APPLICATION TO TWO-DIMENSIONAL SEPARATIONS;632
11.7.1;ABSTRACT;632
11.7.2;KEYWORDS;632
11.7.3;INTRODUCTION;632
11.7.4;METHODOLOGY;633
11.7.5;RESULTS AND DISCUSSION;633
11.7.6;REFERENCES;635
11.8;CHAPTER 133.
THE SEPARATION OF SERUM PROTEINS BY CHROMA TOFOCUSING;636
11.8.1;ABSTRACT;636
11.8.2;INTRODUCTION;636
11.8.3;MATERIALS AND METHODS;637
11.8.4;RESULTS AND DISCUSSION;637
11.8.5;REFERENCES;639
11.9;CHAPTER 134.
CHROMATOFOCUSING APPLIED TO THE SEPARATION OF HUMAN HEMOGLOBINS AND GLOBIN CHAINS;640
11.9.1;ABSTRACT;640
11.9.2;KEYWORDS;640
11.9.3;INTRODUCTION;640
11.9.4;MATERIALS AND METHODS;640
11.9.5;MATERIALS;640
11.9.6;CHROMATOGRAPHIC EQUIPMENT AND PROCEDURES;641
11.9.7;RESULTS;641
11.9.8;DISCUSSION;643
11.9.9;ACKNOWLEDGEMENTS;643
11.9.10;REFERENCES;643
11.10;CHAPTER 135.
BASIC PRINCIPLES USED IN THE SELECTION OF MONOBEADS™ ION EXCHANGERS FOR THE SEPARATION OF BIOPOLYMERS;646
11.10.1;ABSTRACT;646
11.10.2;KEYWORDS;646
11.10.3;INTRODUCTION;646
11.10.4;MATERIALS AMD METHODS;648
11.10.5;CONCLUSIONS;653
11.11;CHAPTER 136.
PHYSICOCHEMICAL CONSIDERATIONS IN THE USE OF MONOBEADS™ FOR THE SEPARATION OF BIOLOGICAL MOLECULES;654
11.11.1;ABSTRACT;654
11.11.2;KEYWORDS;654
11.11.3;INTRODUCTION;654
11.11.4;DESCRIPTION OF THE EXCHANGERS;655
11.11.5;CONTRIBUTIONS;659
11.11.6;REFERENCES;659
11.12;CHAPTER 137. FAST PROTEIN SEPARATIONS ON MONO O™, MONO S™ AND MONO P™;660
11.12.1;ABSTRACT;660
11.12.2;KEYWORDS;660
11.12.3;INTRODUCTION;660
11.12.4;RESULT AND DISCUSSION;660
11.12.5;REFERENCES;661
11.13;CHAPTER 138.
RECOMMENDATIONS FOR OBTAINING OPTIMAL SEPARATIONS ON MONOBEAD™ ION EXCHANGERS;666
11.13.1;ABSTRACT;666
11.13.2;KEYWORDS;666
11.13.3;INTRODUCTION;666
11.13.4;RESULTS AND DISCUSSION;666
11.13.5;REFERENCES;668
11.14;CHAPTER 139.
SAMPLE LOADING CAPACITY ON MONOBEADSTM JON EXCHANGERS;672
11.14.1;ABSTRACT;672
11.14.2;KEY WORDS;672
11.14.3;INTRODUCTION;672
11.14.4;RESULTS AND DISCUSSION;673
11.14.5;REFERENCES;676
11.15;CHAPTER 140.
TWO DIMENSIONAL ANALYSIS OF HUMAN SERA BY CHROMATOFOCUSING ON MONO PTM FOLLOWED BY FUSED ROCKET IMMUNOELECTROPHORESIS;678
11.15.1;ABSTRACT;678
11.15.2;KEYWORDS;678
11.15.3;INTRODUCTION;678
11.15.4;MATERIALS AND METHODS;679
11.15.5;REFERENCES;680
11.16;CHAPTER 141.
ANALYSIS OF HUMAN BLOOD PLASMA BY CHROMATOFOCUSING ON MONO P™ FOLLOWED BY PORE GRADIENT GEL ELECTROPHORESIS;682
11.16.1;ABSTRACT;682
11.16.2;KEYWORDS;682
11.16.3;INTRODUCTION;682
11.16.4;MATERIALS AND METHODS;682
11.16.5;RESULTS AND DISCUSSION;683
11.16.6;REFERENCES;684
11.17;CHAPTER 142.
CHROMATOFOCUSING OF DESIALYLATED HUMAN TRANSFERRIN ON MONO P™;686
11.17.1;ABSTRACT;686
11.17.2;KEYWORDS;686
11.17.3;INTRODUCTION;686
11.17.4;MATERIALS AND METHODS;686
11.17.5;CONCLUSIONS;687
11.17.6;REFERENCES;690
11.18;CHAPTER 143.
IMMUNOAFFINITY CHROMATOGRAPHY WITH MONOCLONAL ANTIBODIES;692
11.18.1;ABSTRACT;692
11.18.2;KEYWORDS;692
11.18.3;INTRODUCTION;692
11.18.4;MATERIALS AND METHODS;693
11.18.5;RESULTS AND DISCUSSION;693
11.18.6;ACKNOWLEDGEMENTS;695
11.18.7;REFERENCES;695
11.19;CHAPTER 144.
SEPARATION OF COPPER-BINDING PEPTIDES FROM HUMAN CERULOPLASMIN BY METAL CHELA TE AFFINITY CHROMATOGRAPHY AND HPLC;696
11.19.1;ABSTRACT;696
11.19.2;KEYWORDS;696
11.19.3;INTRODUCTIQN;696
11.19.4;MATERIALS AMD METHODS;697
11.19.5;RESULTS AND DISCUSSION;697
11.19.6;CONCLUSION;700
11.19.7;ACKNOWLEDGEMENTS;701
11.19.8;REFERENCES;701
11.20;CHAPTER 145.
CHROMATOGRAPHY OF SERUM PROTEINS ON IMMOBILIZED CIBACRON BLUE F3GA;702
11.20.1;ABSTRACTS;702
11.20.2;KEYWORDS;702
11.20.3;INTRODUCTION;702
11.20.4;EXPERIMENTAL;702
11.20.5;RESULTS AND DISCUSSION;703
11.20.6;REFERENCES;705
11.21;CHAPTER 146.
CHROMATOGRAPHY OF PIG PITUITARY EXTRACTS ON INACTIVATED KALLIKREIN SEPHAROSE;706
11.21.1;ABSTRACT;706
11.21.2;KEYWORDS;706
11.21.3;INTRODUCTION;706
11.21.4;MATERIALS AND METHODS;707
11.21.5;RESULTS;707
11.21.6;DISCUSSION;709
11.21.7;REFERENCES;709
11.22;CHAPTER 147.
PURIFICATION OF HUMAN LYMPHOCYTE ECTO-5' NUCLEOTIDASE IN ORDER TO PREPARE A MONOCLONAL ANTIBODY;710
11.22.1;ABSTRACT;710
11.22.2;KEY WORDS;710
11.22.3;INTRODUCTION;710
11.22.4;MATERIALS AND METHODS;711
11.22.5;RESULTS;711
11.22.6;ACKNOWLEDGEMENTS;712
11.22.7;REFERENCES;713
11.23;CHAPTER 148.
HIGH PRESSURE LIQUID CHROMATOGRAPHY USING AMPHOLYTE DISPLACEMENT;714
11.23.1;ABSTRACT;714
11.23.2;KEYWORDS;714
11.23.3;INTRODUCTION;714
11.23.4;MATERIAL AND METHODS;715
11.23.5;RESULTS AND DISCUSSION;715
11.23.6;CONCLUSION;717
11.23.7;REFERENCES;717
11.24;CHAPTER 149.
HIGH SPEED GEL FILTRATION AS A TOOL TO OPTIMIZE PROTEIN FRAGMENTATION;718
11.24.1;ABSTRACT;718
11.24.2;KEYWORDS;718
11.24.3;INTRODUCTION;718
11.24.4;MATERIAL AND METHODS;719
11.24.5;RESULTS AND DISCUSSION;719
11.24.6;REFERENCES;721
11.25;CHAPTER 150.
REVERSE-PHASE HPLC OF PROTEINS USING LARGE PORE SILICA BASED SUPPORTS;722
11.25.1;ABSTRACT;722
11.25.2;KEY WORDS;722
11.25.3;Introduction;722
11.25.4;SUMMARY;725
11.25.5;REFERENCES;725
11.26;CHAPTER 151.
ASSESSMENT STUDY ON THE USE OF THE LOW ANGLE LASER LIGHT SCATTERING TECHNIQUE IN COMBINATION WITH THE HIGH PERFORMANCE POROUS SILICA GEL CHROMATOGRAPHY;726
11.26.1;ABSTRACT;726
11.26.2;KEYWORDS;726
11.26.3;INTRODUCTION;726
11.26.4;EXPERIMENTAL;726
11.26.5;RESULTS;727
11.26.6;DISCUSSION;728
11.26.7;ACKNOWLEDGEMENTS;729
11.26.8;REFERENCES;729
11.27;CHAPTER 152.
COMBINED UV- AND ALKALINE HYDROLYSIS/o-PHTHAL ALDEHYDE REACTION DETECTION IN PREPARATIVE HPLC OF PROTEINS AND PEPTIDES WITH SAMPLES FROM COMPLEX BIOLOGICAL FLUIDS;730
11.27.1;ABSTRACT;730
11.27.2;KEYWORDS;730
11.27.3;INTRODUCTION;730
11.27.4;EXPERIMENTAL;731
11.27.5;INSTRUMENT PERFORMANCE;732
11.27.6;ACKNOWLEDGEMENT;732
11.27.7;REFERENCES;732
11.28;CHAPTER 153.
THE USE OF SIZE EXCLUSION AND d 8 REVERSE PHASE HPLC COLUMNS FOR SEPARATING THE COMPONENT POLYPEPTIDES OF la ANTIGEN MEMBRANE PROTEINS;734
11.28.1;MATERIALS AND METHODS;735
11.28.2;RESULTS AND DISCUSSION;735
11.28.3;ACKNOWLEDGEMENT;737
11.28.4;REFERENCES;737
11.29;CHAPTER 154.
ISOLATION AND CHARACTERIZATION OF INTRACELLULAR Ca2 + -BINDING PROTEINS BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;738
11.29.1;ABSTRACT;738
11.29.2;KEYWORDS;738
11.29.3;INTRODUCTION;738
11.29.4;ACKNOWLEDGEMENT;741
11.29.5;REFERENCES;741
11.30;CHAPTER 155.
EVALUATION OF COMMERCIAL RP-HPLC COLUMNS FOR THE SEPARATION OF PEPTIDES FROM PORCINE CARDIAC MYOSIN LIGHT CHAIN L27;742
11.30.1;ABSTRACT;742
11.30.2;KEYWORDS;742
11.30.3;INTRODUCTION;742
11.30.4;MATERIALS and METHODS;742
11.30.5;RESULTS;743
11.30.6;DISCUSSION;746
11.30.7;REFERENCES;746
11.31;CHAPTER 156.
THE OPTIMIZATION OF RP-HPLC OF PROTEINS WITH LARGE PORE-SIZE SHORT ALKYLCHAIN-BONDED SILICA (ULTRAPORERPSC) AND ITS APPLICATION TO EPIDERMAL GROWTH FACTOR;748
11.31.1;ABSTRACT;748
11.31.2;INTRODUCTION;748
11.31.3;MATERIALS AND METHODS;748
11.31.4;RESULTS AND DISCUSSION;749
11.31.5;ACKNOWLEDGEMENTS;751
11.31.6;REFERENCES;751
11.32;CHAPTER 157.
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY OF PEPTIDES ON MACRORETICULAR POLYSTYRENE RESINS;752
11.32.1;ABSTARACT;752
11.32.2;KEY WORDS;752
11.32.3;INTRODUCTION;752
11.32.4;MATERIALS AND METHODS;752
11.32.5;RESULTS AND DISCUSSION;753
11.32.6;Conclusion;755
11.32.7;REFERENCES;755
11.33;CHAPTER 158.
HPLC SEPARATION OF AXONALLY TRANSPORTED PROTEINS IN SCIATIC NERVES;756
11.33.1;ABSTRACT;756
11.33.2;INTRODUCTION;756
11.33.3;METHODS AND MATERIALS;756
11.33.4;RESULTS;757
11.33.5;DISCUSSION;759
11.33.6;ACKNOWLEDGEMENT;759
11.33.7;REFERENCES;759
11.34;CHAPTER 159.
IMMUNE COMPLEX ANALYSIS BY A COMBINATION OF HIGH PRESSURE LIQUID GEL PERMEATION CHROMATOGRAPHY (HPLC GPC) AND ENZYME IMMUNOASSAY (ELISA);760
11.34.1;ABSTRACT;760
11.34.2;KEYWORDS;760
11.34.3;INTRODUCTION;760
11.34.4;MATERIALS AND METHODS;761
11.34.5;RESULTS AND DISCUSSION;761
11.34.6;ACKNOWLEDGEMENT;763
11.34.7;REFERENCES;763
11.35;CHAPTER 160.
ISOLATION OF THYMOSIN ß8 AND ß9 FROM CALF THYMUS;764
11.35.1;ABSTRACT;764
11.35.2;INTRODUCTION;764
11.35.3;METHODS;764
11.35.4;RESULTS AND DISCUSSION;765
11.35.5;ACKNOWLEDGEMENT;767
11.35.6;REFERENCES;767
12;AUTHOR INDEX;768
13;SUBJECT INDEX;796